Immunohistochemical and molecular markers in the diagnosis of hepatocellular carcinoma

Advances in Anatomic Pathology

Volumn 11, Issue 5, 2004, Pages 239-249

  Varma, Vijay ^a,b   Cohen, Cynthia ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Diagnostic markers; Hepatocellular carcinoma; Immunohistochemical; Molecular

Indexed keywords

TUMOR MARKER;

HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; REVIEW;

CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 16644378805     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/01.pap.0000131822.31576.9d     Document Type: Review

References (109)

1. Bergman S, Graeme-Cook F, Pitman MB. The usefulness of the reticulin stain in the differential diagnosis of liver nodules on fine-needle aspiration biopsy cell block preparations. Mod Pathol. 1997;10:1258-1264. (Pubitemid 28049729)
2. de Boer WB, Segal A, Frost FA, et al. Cytodiagnosis of well differentiated hepatocellular carcinoma: can indeterminate diagnoses be reduced? Cancer. 1999;87:270-277. (Pubitemid 29503481)
3. Hurlimann J, Gardiol D. Immunohistochemistry in the differential diagnosis of liver carcinomas. Am J Surg Pathol. 1991;15:280-288.
4. Christensen WN, Boitnott JK, Kuhajda FP. Immunoperoxidase staining as a diagnostic aid for hepatocellular carcinoma. Mod Pathol. 1989;2:8-12.
5. Ma CK, Zarbo RJ, Frierson HF Jr, et al. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver. Am JClin Pathol. 1993;99:551-557. (Pubitemid 23154095)
6. Murakata LA, Ishak KG, Nzeako UC. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 2000;13:874-881. (Pubitemid 30643835)
7. Imoto M, Nishimura D, Fukuda Y, et al. Immunohistochemical detection of alpha-fetoprotein, carcinoembryonic antigen, and ferritin in formalin-paraffin sections from hepatocellular carcinoma. Am J Gastroenterol.1985;80:902-906. (Pubitemid 16199599)
8. Minervini MI, Demetris AJ, Lee RG, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997;10:686-692. (Pubitemid 27321760)
9. Porcell AI, De Young BR, Proca DM, et al. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol. 2000;13:773-778. (Pubitemid 30470167)
10. Johnson DE, Powers CN, Rupp G, et al. Immunocytochemical staining of fine-needle aspiration biopsies of the liver as a diagnostic tool for hepatocellular carcinoma. Mod Pathol. 1992;5:117-123.
11. Carrozza MJ, Calafati SA, Edmonds PR. Immunocytochemical localization of polyclonal carcinoembryonic antigen in hepatocellular carcinomas. Acta Cytol. 1991;35:221-224.
12. Wolber RA, Greene CA, Dupuis BA. Polyclonal carcinoembryonic antigen staining in the cytologic differential diagnosis of primary and metastatic hepatic malignancies. Acta Cytol. 1991;35:215-220.
13. Wee A, Nilsson B. pCEA canalicular immunostaining in fine needle aspiration biopsy diagnosis of hepatocellular carcinoma. Acta Cytol. 1997;41:1147-1155. (Pubitemid 27329694)
14. Nap M, ten Hoor KA, Fleuren GJ. Cross-reactivity with normal antigens in commercial anti-CEA sera, used for immunohistology. The need for tissue controls and absorptions. Am J Clin Pathol. 1983;79:25-31. (Pubitemid 13222187)
15. Wu PC, Fang JW, Lau VK, et al. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996;149:1167-1175. (Pubitemid 26337236)
16. Leong AS, Sormunen RT, Tsui WM, et al. Hep Par 1 and selected antibodies in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma, combined tumours and metastatic carcinoma. Histopathology. 1998;33:318-324. (Pubitemid 28508880)
17. Fasano M, Theise ND, Nalesnik M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen. Mod Pathol. 1998;11:934-938. (Pubitemid 28487210)
18. Lamps LW, Folpe AL. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review. Adv Anat Pathol. 2003;10:39-43.
19. Terracciano LM, Glatz K, Mhawech P, et al. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases. Am J Surg Pathol.2003;27:1302-1312. (Pubitemid 37185821)
20. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl ImmunohistochemMol Morphol. 1995;3:99-107.
21. Ramaekers F, van Niekerk C, Poels L, et al. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am JPathol. 1990;136:641-655. (Pubitemid 20105931)
22. Moll R, Lowe A, Laufer J, et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am JPathol. 1992;140:427-447.
23. Van Eyken P, Sciot R, Desmet VJ. Immunocytochemistry of cytokeratins in primary human liver tumors. APMIS Suppl. 1991;23:77-85.
24. Kwaspen FH, Smedts FM, Broos A, et al. Reproducible and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology. 1997;31:503-516. (Pubitemid 28008013)
25. Tsuji M, Kashihara T, Terada N, et al. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int. 1999;49:310-317. (Pubitemid 29230795)
26. Maeda T, Kajiyama K, Adachi E, et al. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. ModPathol. 1996;9:901-909. (Pubitemid 26319720)
27. Fiorentino M, D'Errico A, Altimari A, et al. High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas. Diagn Mol Pathol. 1999;8:189-194. (Pubitemid 30003333)
28. Fucich LF, Cheles MK, Thung SN, et al. Primary vs metastatic hepatic carcinoma. An immunohistochemical study of 34 cases. Arch PatholLab Med. 1994;118:927-930. (Pubitemid 24271117)
29. Brumm C, Schulze C, Charels K, et al. The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours. Histopathology. 1989;14:503-513. (Pubitemid 19137152)
30. Kim M-K, Park C-K. Variable cytokeratin 7/20 profiles in carcinomas involving the liver. Appl Immunohistochem Mol Morphol . 1999;7:52-57. (Pubitemid 29190271)
31. Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol. 1998;29:1393-1402. (Pubitemid 28563971)
32. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
33. Rullier A, Le Bail B, Fawaz R, et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 2000;24:870-876. (Pubitemid 30366276)
34. Perry A, Parisi JE, Kurtin PJ. Metastatic adenocarcinoma to the brain: an immunohistochemical approach. Hum Pathol. 1997;28:938-943. (Pubitemid 27355554)
35. Miettinen M, Nobel MP, Tuma BT, et al. Keratin 17. Immunohistochemical mapping of its distribution in human epithelial tumors and its potential applications. Appl Immnohistochem. 1997;5:152-159.
36. Ordonez NG, Manning JT Jr. Comparison of alpha-1-antitrypsin and alpha-1-antichymotrypsin in hepatocellular carcinoma: an immunoperoxidase study. Am J Gastroenterol. 1984;79:959-963. (Pubitemid 15224052)
37. Sosolik RC, McGaughy VR, De Young BR. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol. 1997;10:716-719. (Pubitemid 27321764)
38. Proca DM, Niemann TH, Porcell AI, et al. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. Appl Immunohistochem Mol Morphol.2000;8:120-125. (Pubitemid 30609972)
39. Van de Rijn MRR. CD34. A review. Appl Immunohistochemistry. 1994;2:71-80.
40. Ruck P, Xiao JC, Kaiserling E. Immunoreactivity of sinusoids in hepatocellular carcinoma. An immunohistochemical study using lectin UEA-1 and antibodies against endothelial markers, including CD34. Arch Pathol Lab Med. 1995;119:173-178.
41. Ruck P, Xiao JC, Kaiserling E. QBend 10 (CD34) in the diagnosis of hepatocellular carcinoma. Histopathology. 1996;29:593-594.
42. Maeda T, Adachi E, Kajiyama K, et al. CD34 expression in endothelial cells of small hepatocellular carcinoma: its correlation with tumour progression and angiographic findings. J Gastroenterol Hepatol. 1995;10:650-654.
43. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol.1998;22:656-662. (Pubitemid 28280267)
44. Cui S, Hano H, Sakata A, et al. Enhanced CD34 expression of sinusoidlike vascular endothelial cells in hepatocellular carcinoma. Pathol Int.1996;46:751-756. (Pubitemid 26353225)
45. Kimura H, Nakajima T, Kagawa K, et al. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver. 1998;18:14-19. (Pubitemid 28127752)
46. Scott FR, el-Refaie A, More L, et al. Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma. Histopathology. 1996;28:472-474. (Pubitemid 26157698)
47. Dhillon AP, Colombari R, Savage K, et al. An immunohistochemical study of the blood vessels within primary hepatocellular tumours. Liver.1992;12:311-318.
48. Gottschalk-Sabag S, Ron N, Glick T. Use of CD34 and factor VIII to diagnose hepatocellular carcinoma on fine needle aspirates. Acta Cytol.1998;42:691-696. (Pubitemid 28274779)
49. Kin M, Torimura T, Ueno T, et al. Sinusoidal capillarization in small hepatocellular carcinoma. Pathol Int. 1994;44:771-778. (Pubitemid 24320465)
50. Tanigawa N, Lu C, Mitsui T, et al. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology. 1997;26:1216-1223. (Pubitemid 27509306)
51. Sun HC, Tang ZY, Li XM, et al. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol.1999;125:419-426.
52. El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998;27:1554-1562. (Pubitemid 28264678)
53. Terada T, Nakanuma Y. Expression of ABH blood group antigens, Ulexeuropaeus agglutinin I, and type IV collagen in the sinusoids of hepatocellular carcinoma. Arch Pathol Lab Med. 1991;115:50-55.
54. Yamamoto A, Dhar DK, El-Assal ON, et al. Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. J Hepatol. 1998;29:290-299. (Pubitemid 28352815)
55. Terada T, Nakanuma Y. Arterial elements and perisinusoidal cells in borderline hepatocellular nodules and small hepatocellular carcinomas. Histopathology. 1995;27:333-339.
56. Yoshida K, Tadaoka Y, Manabe T. Expression of laminin in hepatocellular carcinoma: an adjunct for its histological diagnosis. Jpn J Clin Oncol.1996;26:70-76. (Pubitemid 126467437)
57. Torimura T, Ueno T, Kin M, et al. Coordinated expression of integrin alpha6beta1 and laminin in hepatocellular carcinoma. Hum Pathol.1997;28:1131- 1138. (Pubitemid 27446598)
58. Chedid A, Chejfec G, Eichorst M, et al. Antigenic markers of hepatocellular carcinoma. Cancer. 1990;65:84-87. (Pubitemid 20026815)
59. Ganjei P, Nadji M, Albores-Saavedra J, et al. Histologic markers in primary and metastatic tumors of the liver. Cancer. 1988;62:1994-1998. (Pubitemid 18261826)
60. Sato K, Tanaka M, Kusaba T, et al. Immunohistochemical demonstration of alpha-fetoprotein in small hepatocellular carcinoma. Oncol Rep.1998;5:355-358. (Pubitemid 28100088)
61. McCluggage WG, Maxwell P, Patterson A, et al. Immunohistochemical staining of hepatocellular carcinoma with monoclonal antibody against inhibin. Histopathology. 1997;30:518-522. (Pubitemid 27254940)
62. Bedrossian CWM, Davila RM, Merenda G. Immunocytochemical evaluation of liver fine-needle aspirations. Arch Pathol Lab Med. 1989;113:1225-1230. (Pubitemid 19275677)
63. Reintoft I, Hagerstrand I. Demonstration of alpha 1-antitrypsin in hepatomas. Arch Pathol Lab Med. 1979;103:495-498.
64. Palmer PE, Wolfe HJ. Alpha-antitrypsin deposition in primary hepatic carcinomas. Arch Pathol Lab Med. 1976;100:232-236. (Pubitemid 8228032)
65. Jian J, Manda Z, Bocheng W, et al. Radioimmunoassay of human cardiac acidic isoferritin: a new index for hepatic cancer. Chinese Med J. 1998;111:150-153.
66. Cohen C, Berson SD, Shulman G, et al. Immunohistochemical ferritin in hepatocellular carcinoma. Cancer. 1984;53:1931-1935. (Pubitemid 14127650)
67. Weitz IC, Liebman HA. Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatol. 1993;18:990-997.
68. Terada T, Nakanuma Y. An immunohistochemical survey of amylase isoenzymes in cholangiocarcinoma and hepatocellular carcinoma. ArchPathol Lab Med. 1993;117:160-162. (Pubitemid 23057618)
69. Kew MC, Fisher JW. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer. 1986;58:2485-2488. (Pubitemid 17191612)
70. Lee FY, Lee SD, Tsai YT, et al. Serum C-reactive protein as a serum marker for the diagnosis of hepatocellular carcinoma. Cancer. 1989;63:1567-1571. (Pubitemid 19093283)
71. Miyazaki K, Noda N, Okada S, et al. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy. 1998;11:277-288. (Pubitemid 29044695)
72. Cohen MB, Beckstead JH, Ferrell LD, et al.: Enzyme histochemistry of hepatocellular neoplasms. Am J Surg Pathol. 1986;10:789-794. (Pubitemid 17176941)
73. Roskams T, Willems M, Campos RV, et al. Parathyroid hormone-related peptide expression in primary and metastatic liver tumours. Histopathol.1993;23: 519-525. (Pubitemid 24034818)
74. Iezzoni JC, Mills SE, Pelkey TJ, et al. Inhibin is not an immunohistochemical marker for hepatocellular carcinoma. An example of the potential pitfall in diagnostic immunohistochemistry caused by endogenous biotin. Am J Clin Pathol. 1999;111:229-234. (Pubitemid 29054951)
75. Chen S, Mandavilli S, Mandich D, et al. Value of thyroid transcription factor (TTF-1) and antihepatocyte monoclonal antibodies in differentiating hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) in liver. Mod Pathol. 2001;14:193A.
76. Yamaguchi K, Nalesnik MA, Carr BI. In situ hybridization of albumin mRNA in normal liver and liver tumors: identification of hepatocellular origin. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64:361-365.
77. Krishna M, Lloyd RV, Batts KP. Detection of albumin messenger RNA in hepatic and extrahepatic neoplasms. A marker of hepatocellular differentiation. Am J Surg Pathol. 1997;21:147-152. (Pubitemid 27084053)
78. Papotti M, Pacchioni D, Negro F, et al. Albumin gene expression in liver tumors: diagnostic interest in fine needle aspiration biopsies. ModPathol. 1994;7:271-275.
79. Murray GI, Paterson PJ, Ewen SW, et al. In situ hybridisation of albumin mRNA in normal liver and hepatocellular carcinoma with a digoxigenin labelled oligonucleotide probe. J Clin Pathol. 1992;45:21-24.
80. Stephen MR, Oien K, Ferrier RK, et al. Effusion cytology of hepatocellular carcinoma with in situ hybridisation for human albumin. J ClinPathol. 1997;50:442-444. (Pubitemid 27278454)
81. Roberts CC, Colby TV, Batts KP. Carcinoma of the stomach with hepatocyte differentiation (hepatoid adenocarcinoma). Mayo Clin Proc.1997;72:1154-1160. (Pubitemid 27528329)
82. Oliveira AM, Erickson LA, Burgart LJ, et al. Differentiation of primary and metastatic clear cell tumors in the liver by in situ hybridization for albumin messenger RNA. Am J Surg Pathol. 2000;24:177-182. (Pubitemid 30078705)
83. Leonhardt U, Ritzel U, Ottleben M, et al. Detection of circulating albumin-mRNA by RT-PCR does not indicate metastasizing hepatocellular carcinoma. Langenbecks Arch Chir. 1997;382:83-86. (Pubitemid 27179513)
84. Nakashio R, Kitamoto M, Tahara H, et al. Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinoma. Int J Cancer. 1997;74:141-147. (Pubitemid 27234501)
85. Shimada M, Hasegawa H, Gion T, et al. The role of telomerase activity in hepatocellular carcinoma. Am J Gastroenterol. 2000;95:748-752. (Pubitemid 30123914)
86. Nagao K, Tomimatsu M, Endo H, et al. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol. 1999;34:83-87. (Pubitemid 29112340)
87. Kawakami Y, Kitamoto M, Nakanishi T, et al. Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues. Oncogene. 2000;19:3888-3893. (Pubitemid 30658979)
88. Wilkens L, Bredt M, Flemming P, et al. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol. 2001;193:476-482. (Pubitemid 32266816)
89. Balsara BR, Pei J, De Rienzo A, et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer.2001;30:245-253. (Pubitemid 32126200)
90. Wong N, Lai P, Lee SW, et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol. 1999;154:37-43. (Pubitemid 29031609)
91. Kusano N, Shiraishi K, Kubo K, et al. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology. 1999;29:1858-1862. (Pubitemid 29247061)
92. Huang SF, Hsu HC, Fletcher JA. Investigation of chromosomal aberrations in hepatocellular carcinoma by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1999;111:21-27. (Pubitemid 29214330)
93. Nolte M, Werner M, Nasarek A, et al. Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol. 1998;51:47-51. (Pubitemid 28122586)
94. Wilkens L, Bredt M, Flemming P, et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn.2001;3:68-73. (Pubitemid 32440245)
95. Naka TN, Kaneko T, Kaibara N, et al. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res. 1998;18:555-564. (Pubitemid 28174872)
96. Akyol G, Dursun A, Poyraz A, et al. P53 and proliferating cell nuclear antigen (PCNA) expression in non-tumoral liver diseases. Pathol Int.1999;49:214-221. (Pubitemid 29210548)
97. Itoh T, Shiro T, Seki T, et al. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma. Int J Mol Med.2000;6:137-142.
98. Wells SJ, DeRose PB, Cohen C. Image cytometric comparison of proliferating cell nuclear antigen and MIB-1 staining in hepatocellular carcinoma and adjacent liver tissue. Cytometry. 1996;26:198-203. (Pubitemid 26341313)
99. Jain R, Malhotra V, Kumar N, et al. Nucleolar organizer regions in cirrhosis and hepatocellular carcinoma. Trop Gastroenterol. 1998;19:100-101.
100. Crocker J, McGovern J. Nucleolar organiser regions in normal, cirrhotic, and carcinomatous livers. J Clin Pathol. 1988;41:1044-1048.
101. Siddiqui MS, Soomro IN, Kayani N, et al. Assessment of nucleolar organizer regions (NORs) in proliferative conditions of the liver. PatholRes Pract. 1999;195:421-426. (Pubitemid 29294991)
102. Haglund C, Lindgren J, Roberts PJ, et al. Difference in tissue expression of tumor markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma. Br J Cancer. 1991;63:386-389.
103. Pastolero GC, Wakabayashi T, Oka T, et al. Tissue polypeptide antigen. A marker antigen differentiating cholangiolar tumors from other hepatic tumors. Am J Clin Pathol. 1987;87:168-173. (Pubitemid 17022454)
104. Uchida T, Nagai H, Gotoh K, et al. Expression pattern of a newly recognized protein, LECT2, in hepatocellular carcinoma and its premalignant lesion. Pathol Int. 1999;49:147-151. (Pubitemid 29133474)
105. Jovanovic R, Jagirdar J, Thung SN, et al. Blood-group-related antigen Lewis(x) and Lewis(y) in the differential diagnosis of cholangiocarcinoma and hepatocellular carcinoma. Arch Pathol Lab Med. 1989;113:139-144.
106. Sciot R, Paterson AC, van Eyken P, et al. Transferrin receptor expression in human hepatocellular carcinoma an immunohistochemical study of 34 cases. Histopathology. 1988;12:53-63.
107. Sasaki M, Yamato T, Nakanuma Y. Expression of sialyl-Tn, Tn and T antigens in primary liver cancer. Pathol Int. 1999;49:325-331. (Pubitemid 29230797)
108. Cao Y, Karsten U, Otto G, et al. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and -2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. VirchowsArch. 1999;434:503-509. (Pubitemid 29281307)
109. Nagasue N, Kohno H, Yamanoi A, et al. Progesterone receptor in hepatocellular carcinoma. Correlation with androgen and estrogen receptors. Cancer. 1991;67:2501-2505.